Beddow v Cayzer

A joint venture may amount to a partnership, with fiduciary duties, where the parties agree to carry on business together with a view to profit. Terms discussed during negotiations, including proposed funding levels and minimum shareholdings in a company yet to be formed, may remain too uncertain to enforce even though a binding joint venture exists.

Partnership assets include confidential information and opportunities obtained through the venture. A partner must not exclude the other participants or exploit those assets for personal benefit. Where a partner acquires shares or subscription rights through the venture, those rights may be held on trust for the others and may require an account.

The claimant and Mr Brunnock developed a proposal to consolidate veterinary practices and approached Mr Galliers-Pratt for funding. The claimant alleged that Mr Galliers-Pratt, acting with authority from his brother, the defendant, agreed to join the venture, provide or procure finance, and secure minimum equity interests for the promoters.

The defendant later took control of the financing and excluded the claimant and Mr Brunnock from important discussions. Funding was eventually obtained from Nash Sells & Partners Ltd, and CVS (UK) Ltd was incorporated. The claimant rejected an offer of 1.5% of the ordinary shares and sought declarations and equitable relief based on the alleged agreement, an alternative joint venture, and a Pallant v Morgan equity.

The central issues were whether a joint venture agreement existed, whether its more detailed funding and shareholding terms were enforceable, and what rights arose from the defendant’s use of venture assets.

1. Joint venture and partnership. The court found that an agreement was reached in February 1998 between the claimant, Mr Brunnock and Mr Galliers-Pratt. It was an agreement to participate in a joint venture which, on its terms, amounted at least to a partnership at will: the parties were to carry on business together with a view to profit. The agreement carried fiduciary duties. The defendant was also a party because Mr Galliers-Pratt had authority to act on his behalf.
2. Uncertain terms. The alleged commitments to obtain £5 million of equity funding, £5–10 million of debt finance, underwrite the investment and secure minimum 7% shareholdings were too vague to be legally enforceable. The date for obtaining funding, the company’s constitutional arrangements and the terms of the debt funding had not been settled. Those conclusions did not prevent the existence of the wider joint venture agreement.
3. Venture assets and exclusion. Confidential information obtained during the venture, including the opportunity to acquire Barton Veterinary Hospital, was a partnership asset. The defendant was not entitled to exclude the claimant and Mr Brunnock or use that information for his own benefit. His exclusion of them from management, funding and investor discussions breached his duties of good faith.
4. Later financing. The original agreement contemplated overseas or individual investors and did not include approaches to Arthur Andersen or venture capitalists. Once the claimant and Mr Brunnock acquiesced in that route, their rights became subject to proper conditions attached to the new financing, including payment on subscription. Had the minimum shareholding term been enforceable, their acquiescence would also have varied or waived it.
5. Shares and relief. The court found that 15% of CVSUK’s ordinary shares was available to the defendant for sharing with the claimant and Mr Brunnock. After Mr Brunnock accepted 1.5%, the defendant remained accountable for 13.5%, including 67,500 shares held for the claimant. The defendant’s power in relation to shares subscribed by Perth Business Corporation was likewise held on trust. The court granted a declaration and reserved the form of the declaration and further relief.